会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • CYP2A6 gene judgment methods
    • CYP2A6基因判断方法
    • US06660478B1
    • 2003-12-09
    • US09959433
    • 2001-10-25
    • Tetsuya Kamataki
    • Tetsuya Kamataki
    • C07H2102
    • C12Q1/6876C12Q2600/156C12Q2600/172
    • There are provided a method of determining a genotype of CYP2A6 gene on the basis of a difference in gene structures of a wild-type gene of CYP2A6 and at least one kind of mutant-type gene associated with mutation of CYP2A6 gene; the method mentioned above, wherein one kind of mutant-type gene associated with mutation of CYP2A6 gene is used, and the mutant-type gene is conversion-type CYP2A6 gene comprising the nucleotide sequence of SEQ ID NO: 4; the method mentioned above, wherein homozygous deletion and heterozygous deletion of CYP2A6 gene are determined by using at least two kinds of mutant-type genes associated with mutation of CYP2A6 gene; a method of determining a genotype of a CYP gene, characterized by carrying out a method comprising the method mentioned above to determine the genotype of the CYP gene; a diagnostic kit for determining a genotype of CYP2A6 gene, comprising 5′-primer capable of hybridizing to both exon 8 of CYP2A6 gene and exon 8 of CYP2A 7 gene, 3′-primer capable of specifically hybridizing to exon 9 of CYP2A6 gene, AccII or an isoschizomer thereof, and Eco81I or an isoschizomer thereof; and the like.
    • 提供了基于CYP2A6的野生型基因的基因结构的差异和与CYP2A6基因突变相关的至少一种突变型基因的CYP2A6基因的基因型的方法。 使用上述的方法,其中使用与CYP2A6基因突变相关的一种突变型基因,突变型基因是包含SEQ ID NO:4的核苷酸序列的转化型CYP2A6基因; 通过使用与CYP2A6基因突变相关的至少两种突变型基因来确定CYP2A6基因的纯合缺失和杂合缺失的方法, 确定CYP基因的基因型的方法,其特征在于进行包含上述方法的方法以确定CYP基因的基因型; 用于确定CYP2A6基因的基因型的诊断试剂盒,其包含能够与CYP2A6基因的外显子8和CYP2A7基因的外显子8杂交的5'-引物,能够与CYP2A6基因的外显子9特异性杂交的3'-引物,AccII 或其异构体,和Eco81I或其异构体; 等等。
    • 2. 发明授权
    • .beta.-glucuronidase inhibitor
    • β-葡萄糖醛酸苷酶抑制剂
    • US5447719A
    • 1995-09-05
    • US30346
    • 1993-03-25
    • Tetsuya Kamataki
    • Tetsuya Kamataki
    • A61K31/47A61K31/70A61K36/00A61K36/53A61K36/538A61K36/539A61P1/00A61P35/00A61P43/00C07H17/00C07H17/07A61K35/78
    • C07H17/00A61K31/70A61K36/538A61K36/539
    • A .beta.-glucuronidase inhibitor comprising at least one compound selected from the group consisting of baicalin, oroxylin A-7-O-glucuronide and luteolin-3'-glucuronide; an extract of scutellaria root (baikal skullcap; Scutellariae Radix) and/or schizonepeta spike (Japanese catnip; Schizonepelae Spica); or a Chinese and Japanese traditional prescription comprised of scutellaria root (baikal skullcap; Scutellariae Radix) and/or schizonepeta spike (Japanese catnip; Schizonepelae Spica) as a crude drug. The .beta.-glucuronidase inhibitor can relieve the adverse effect, especially diarrhea, caused in the administration of a compound represented by the following formula I ##STR1##
    • PCT No.PCT / JP92 / 00988 Sec。 371日期1993年3月25日 102(e)1993年3月25日PCT提交1992年8月3日PCT公布。 出版物WO93 / 02684 日本二月十八日,1993年。一种β-葡糖醛酸糖苷酶抑制剂,其包含至少一种选自黄芩苷,奥曲霉素A-7-O-葡糖苷酸和木犀草素-3'-葡糖苷酸的化合物; 黄芩提取物(白al cap;黄芩)和/或荆芥(Schizonepeta spike)(日本catnip; Schizonepelae Spica); 或由中国和日本传统处方组成的黄芩根(贝加尔骷髅帽,黄芩)和/或荆芥(Schizonepeta spike)(日本猫鼬),作为生药。 β-葡萄糖醛酸苷酶抑制剂可以缓解由下式I表示的化合物给药引起的副作用,特别是腹泻